What you should know:
1. For the quarter, Motus reported clinical results from its latest study — showing that the Pure-Vu system increased bowel preparation rates from a baseline of 38 percent to 96 percent. The Pure-Vu system is a device used during colonoscopy to clean a poorly prepared colon. The company also received FDA 510(k) clearance for the Pure-Vu and made several appointments to bolster its leadership staff.
2. Motus’ next near-term milestone is the commercial launch of the Pure-Vu system. The company has not yet specified when the launch will occur.
3. For the year to date, Motus has posted a net loss of $12 million.
4. Motus has $13.8 million in assets through the second quarter and $22.95 million in assets through the year to date.
Read the entire source here.
More articles on surgery centers:
6 spine-focused ASCs opened or announced this year
The 10 best states for healthcare l 2019
Physician-managed Altair Health opens spine ASC — 3 insights
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
